Gastric Ulcers - Pipeline Review, H1 2018

  • ID: 4479916
  • Report
  • 44 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Astellas Pharma Inc
  • RaQualia Pharma Inc
  • XuanZhu Pharma Co Ltd
  • MORE
Gastric Ulcers - Pipeline Review, H1 2018

Summary:

This latest Pharmaceutical and Healthcare disease pipeline guide Gastric Ulcers - Pipeline Review, H1 2018, provides an overview of the Gastric Ulcers (Gastrointestinal) pipeline landscape.

Gastric ulcer is a painful sore or ulcer in the lining of stomach. The most common cause of gastric ulcer is Helicobacter pylori bacterial infection. Symptoms include pain, bloating, retching, nausea or vomiting and unexplained weight loss. Predisposing factors include smoking and alcoholism. Treatment includes antibiotics and antacids.

Report Highlights:

This Pharmaceutical and Healthcare latest pipeline guide Gastric Ulcers - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Gastric Ulcers (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Gastric Ulcers (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Gastric Ulcers and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase II, Phase I and Preclinical stages are 1, 2, 4 and 4 respectively.

Gastric Ulcers (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Gastric Ulcers (Gastrointestinal).
  • The pipeline guide reviews pipeline therapeutics for Gastric Ulcers (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Gastric Ulcers (Gastrointestinal) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Gastric Ulcers (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Gastric Ulcers (Gastrointestinal)
Reasons for Purchase:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Gastric Ulcers (Gastrointestinal).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Gastric Ulcers (Gastrointestinal) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Astellas Pharma Inc
  • RaQualia Pharma Inc
  • XuanZhu Pharma Co Ltd
  • MORE
Introduction

Report Coverage

Gastric Ulcers - Overview

Gastric Ulcers - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Gastric Ulcers - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Gastric Ulcers - Companies Involved in Therapeutics Development

Astellas Pharma Inc

Boryung Pharmaceutical Co Ltd

Daewoong Pharmaceutical Co Ltd

Kukje Pharmaceutical Industry Co Ltd

RaQualia Pharma Inc

XuanZhu Pharma Co Ltd

Gastric Ulcers - Drug Profiles

(lafutidine + irsogladine maleate) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ASP-6537 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BGC-001 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

DWJ-1386 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

DWJ-206 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

DWP-14012 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

KBP-3571 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

KJ-14001 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PMKS-005 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SFR-9X0123 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

tegoprazan - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Gastric Ulcers - Dormant Projects

Gastric Ulcers - Discontinued Products

Gastric Ulcers - Product Development Milestones

Featured News & Press Releases

Jul 17, 2013: Sihuan Pharmaceutical Secures SFDA Approval for Anaprazole Sodium Category 1.1 New Drug Clinical Studies

Mar 01, 2010: AstraZeneca Provides An Update On The Status Of Its Arrangements With Merck

Jan 07, 2010: AstraZeneca Reaches Agreements With Teva Pharmaceuticals Regarding Nexium And Prilosec US Patent Litigations

Apr 15, 2008: AstraZeneca Settles US Nexium Patent Litigation with Ranbaxy

Feb 28, 2008: AstraZeneca Provides An Update on the Status of its Arrangements With Merck & Co., Inc.

Dec 10, 2007: FDA Concludes There Is No Increased Risk Of Cardiac Events For Patients Treated With Omeprazole And NEXIUM (Esomeprazole Magnesium)

Jun 01, 2007: AstraZeneca’s Prilosec Patents Upheld By Court

Dec 12, 2003: Astrazeneca Prilosec Patents Upheld by Federal Appeals Court

Aug 08, 2003: Astrazeneca to Seek Triple Damages in Patent Infringement Lawsuit Against Mylan Pharmaceuticals

Oct 23, 2001: Prilosec US litigation

May 02, 2001: Astrazeneca Receives Six Months' Market Exclusivity for Prilosec

May 02, 2001: Court Denies Generic's Application for Summary Judgement on Prilosec Patent

Apr 23, 2001: Astrazeneca Files Lawsuit Against Apotex Corporation and Torpharm for Patent Infringement

Dec 19, 2000: Astrazeneca Wins Losec Patent Litigation in Canada

Oct 20, 2000: Joint FDA Advisory Committee Confirms OTC Prilosec (Omeprazole) Safety and Efficacy

Appendix

Methodology

Coverage

Secondary Research

Secondary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Gastric Ulcers, H1 2018

Number of Products under Development by Companies, H1 2018

Products under Development by Companies, H1 2018

Number of Products by Stage and Target, H1 2018

Number of Products by Stage and Mechanism of Action, H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Gastric Ulcers - Pipeline by Astellas Pharma Inc, H1 2018

Gastric Ulcers - Pipeline by Boryung Pharmaceutical Co Ltd, H1 2018

Gastric Ulcers - Pipeline by Daewoong Pharmaceutical Co Ltd, H1 2018

Gastric Ulcers - Pipeline by Kukje Pharmaceutical Industry Co Ltd, H1 2018

Gastric Ulcers - Pipeline by RaQualia Pharma Inc, H1 2018

Gastric Ulcers - Pipeline by XuanZhu Pharma Co Ltd, H1 2018

Gastric Ulcers - Dormant Projects, H1 2018

Gastric Ulcers - Discontinued Products, H1 2018

List of Figures

Number of Products under Development for Gastric Ulcers, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products by Targets, H1 2018

Number of Products by Stage and Targets, H1 2018

Number of Products by Mechanism of Actions, H1 2018

Number of Products by Stage and Mechanism of Actions, H1 2018

Number of Products by Stage and Routes of Administration, H1 2018

Number of Products by Molecule Types, H1 2018

Number of Products by Stage and Molecule Types, H1 2018
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Astellas Pharma Inc
  • Boryung Pharmaceutical Co Ltd
  • Daewoong Pharmaceutical Co Ltd
  • Kukje Pharmaceutical Industry Co Ltd
  • RaQualia Pharma Inc
  • XuanZhu Pharma Co Ltd
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll